why choose us

First received: December 02, 2022

Clinical Trial: A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Study Status: Completed

Recruit Status: RECRUITING

Condition: Solid Tumor, Adult

Study Type: INTERVENTIONAL


Official Title: An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors

Brief Summary: This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.

Read more